SEC Company Response from TENAX THERAPEUTICS, INC. (TENX) (CIK 0000034956) (TENX) — Feb 19, 2010
TENAX THERAPEUTICS, INC. (TENX) (CIK 0000034956)
Date: Feb. 19, 2010 · CIK: 0000034956 · Accession: 0001193125-10-035127
AI Filing Summary & Sentiment
Reasoning
Referenced dates: January 29, 2010
Letter
Via EDGAR Securities and Exchange Commission Attention: Jim B. Rosenberg, Senior Assistant Chief Accountant Re: SEC letter dated January 29, 2010 regarding Oxygen Biotherapeutics, Inc. Form10-K for the Fiscal Year Ended April 30, 2009 File Number: 002-31909
Dear Mr. Rosenberg:
We have received your letter dated January 29, 2010. Due to the timing of our third quarter filing we will respond to the letter no later than March 3, 2010. If you have any questions, please contact our Chief Financial Officer, Michael Jebsen, (919-806-4618) or the undersigned (919-806-4414).
Kind regards,
/s/ Nancy J.M. Hecox
Nancy J.M. Hecox
VP Legal Affairs, General Counsel
Oxygen Biotherapeutics
2530 Meridian Parkway, Suite 3078
Durham, NC 27713
Office: 919 806-4414/Cell: (919) 809-4682
Fax 919 806-4417
cc: Michael Jebsen, CFO, Oxygen Biotherapeutics, Inc.
Show Raw Text
CORRESP 1 filename1.htm Response Letter Via EDGAR February 19, 2010 Securities and Exchange Commission Station Place 100 F Street, N.E. Washington, D.C. 20549 Attention: Jim B. Rosenberg, Senior Assistant Chief Accountant Re: SEC letter dated January 29, 2010 regarding Oxygen Biotherapeutics, Inc. Form10-K for the Fiscal Year Ended April 30, 2009 File Number: 002-31909 Dear Mr. Rosenberg: We have received your letter dated January 29, 2010. Due to the timing of our third quarter filing we will respond to the letter no later than March 3, 2010. If you have any questions, please contact our Chief Financial Officer, Michael Jebsen, (919-806-4618) or the undersigned (919-806-4414). Kind regards, /s/ Nancy J.M. Hecox Nancy J.M. Hecox VP Legal Affairs, General Counsel Oxygen Biotherapeutics 2530 Meridian Parkway, Suite 3078 Durham, NC 27713 Office: 919 806-4414/Cell: (919) 809-4682 Fax 919 806-4417 cc: Michael Jebsen, CFO, Oxygen Biotherapeutics, Inc.